- Investing Ideas
- U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
11
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
11 companies
Merck
Market Cap: US$274.0b
Operates as a healthcare company worldwide.
MRK
US$109.18
7D
-4.7%
1Y
31.1%
Illumina
Market Cap: US$18.3b
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
ILMN
US$126.74
7D
1.0%
1Y
65.7%
Exelixis
Market Cap: US$11.4b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$44.46
7D
-3.5%
1Y
14.3%
ACADIA Pharmaceuticals
Market Cap: US$3.8b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$22.45
7D
1.5%
1Y
54.1%
ADMA Biologics
Market Cap: US$2.4b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$10.25
7D
-9.0%
1Y
-56.4%
Aurinia Pharmaceuticals
Market Cap: US$2.0b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$15.39
7D
-4.7%
1Y
87.6%
Theravance Biopharma
Market Cap: US$858.4m
A biopharmaceutical company, develops and commercializes medicines in the United States.
TBPH
US$16.74
7D
2.6%
1Y
61.1%
CorMedix
Market Cap: US$586.6m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$7.59
7D
3.5%
1Y
-21.3%
Abeona Therapeutics
Market Cap: US$303.8m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$5.46
7D
-1.1%
1Y
-20.5%
Compugen
Market Cap: US$245.8m
A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
CGEN
US$2.66
7D
-8.9%
1Y
75.0%
Oramed Pharmaceuticals
Market Cap: US$156.9m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$3.88
7D
1.0%
1Y
70.9%